113 related articles for article (PubMed ID: 38190100)
41. PIAS1 confers DNA-binding specificity on the Msx1 homeoprotein.
Lee H; Quinn JC; Prasanth KV; Swiss VA; Economides KD; Camacho MM; Spector DL; Abate-Shen C
Genes Dev; 2006 Apr; 20(7):784-94. PubMed ID: 16600910
[TBL] [Abstract][Full Text] [Related]
42. PIAS1 negatively modulates virus triggered type I IFN signaling by blocking the DNA binding activity of IRF3.
Li R; Pan Y; Shi DD; Zhang Y; Zhang J
Antiviral Res; 2013 Nov; 100(2):546-54. PubMed ID: 24036127
[TBL] [Abstract][Full Text] [Related]
43. Ubc9 and Protein Inhibitor of Activated STAT 1 Activate Chicken Ovalbumin Upstream Promoter-Transcription Factor I-mediated Human CYP11B2 Gene Transcription.
Kurihara I; Shibata H; Kobayashi S; Suda N; Ikeda Y; Yokota K; Murai A; Saito I; Rainey WE; Saruta T
J Biol Chem; 2005 Feb; 280(8):6721-30. PubMed ID: 15611122
[TBL] [Abstract][Full Text] [Related]
44. Pbrm1 Steers Mesenchymal Stromal Cell Osteolineage Differentiation by Integrating PBAF-Dependent Chromatin Remodeling and BMP/TGF-β Signaling.
Sinha S; Biswas M; Chatterjee SS; Kumar S; Sengupta A
Cell Rep; 2020 Apr; 31(4):107570. PubMed ID: 32348751
[TBL] [Abstract][Full Text] [Related]
45. Phosphorylation-dependent interaction of SATB1 and PIAS1 directs SUMO-regulated caspase cleavage of SATB1.
Tan JA; Song J; Chen Y; Durrin LK
Mol Cell Biol; 2010 Jun; 30(11):2823-36. PubMed ID: 20351170
[TBL] [Abstract][Full Text] [Related]
46. PIAS1 interacts with FLASH and enhances its co-activation of c-Myb.
Alm-Kristiansen AH; Lorenzo PI; Molværsmyr AK; Matre V; Ledsaak M; Sæther T; Gabrielsen OS
Mol Cancer; 2011 Feb; 10():21. PubMed ID: 21338522
[TBL] [Abstract][Full Text] [Related]
47. A PIAS1 Protective Variant S510G Delays polyQ Disease Onset by Modifying Protein Homeostasis.
Lee YH; Tsai YS; Chang CC; Ho CC; Shih HM; Chen HM; Lai HL; Lee CW; Lee YC; Liao YC; Yang UC; Cheng TH; Chern Y; Soong BW
Mov Disord; 2022 Apr; 37(4):767-777. PubMed ID: 34951052
[TBL] [Abstract][Full Text] [Related]
48. Identification of the SUMO E3 ligase PIAS1 as a potential survival biomarker in breast cancer.
Chanda A; Chan A; Deng L; Kornaga EN; Enwere EK; Morris DG; Bonni S
PLoS One; 2017; 12(5):e0177639. PubMed ID: 28493978
[TBL] [Abstract][Full Text] [Related]
49. Multisite SUMOylation restrains DNA polymerase η interactions with DNA damage sites.
Guérillon C; Smedegaard S; Hendriks IA; Nielsen ML; Mailand N
J Biol Chem; 2020 Jun; 295(25):8350-8362. PubMed ID: 32350109
[TBL] [Abstract][Full Text] [Related]
50. Regulation of Smad4 sumoylation and transforming growth factor-beta signaling by protein inhibitor of activated STAT1.
Liang M; Melchior F; Feng XH; Lin X
J Biol Chem; 2004 May; 279(22):22857-65. PubMed ID: 15028714
[TBL] [Abstract][Full Text] [Related]
51. Rad18-dependent SUMOylation of human specialized DNA polymerase eta is required to prevent under-replicated DNA.
Despras E; Sittewelle M; Pouvelle C; Delrieu N; Cordonnier AM; Kannouche PL
Nat Commun; 2016 Nov; 7():13326. PubMed ID: 27811911
[TBL] [Abstract][Full Text] [Related]
52. Protein inhibitors of activated STAT (Pias1 and Piasy) differentially regulate pituitary homeobox 2 (PITX2) transcriptional activity.
Wang J; Sun Z; Zhang Z; Saadi I; Wang J; Li X; Gao S; Engle JJ; Kuburas A; Fu X; Yu W; Klein WH; Russo AF; Amendt BA
J Biol Chem; 2013 May; 288(18):12580-95. PubMed ID: 23515314
[TBL] [Abstract][Full Text] [Related]
53. ZNF451 is a novel PML body- and SUMO-associated transcriptional coregulator.
Karvonen U; Jääskeläinen T; Rytinki M; Kaikkonen S; Palvimo JJ
J Mol Biol; 2008 Oct; 382(3):585-600. PubMed ID: 18656483
[TBL] [Abstract][Full Text] [Related]
54. PIAS1-mediated SUMOylation of influenza A virus PB2 restricts viral replication and virulence.
Wang G; Zhao Y; Zhou Y; Jiang L; Liang L; Kong F; Yan Y; Wang X; Wang Y; Wen X; Zeng X; Tian G; Deng G; Shi J; Liu L; Chen H; Li C
PLoS Pathog; 2022 Apr; 18(4):e1010446. PubMed ID: 35377920
[TBL] [Abstract][Full Text] [Related]
55. The STUbL RNF4 regulates protein group SUMOylation by targeting the SUMO conjugation machinery.
Kumar R; González-Prieto R; Xiao Z; Verlaan-de Vries M; Vertegaal ACO
Nat Commun; 2017 Nov; 8(1):1809. PubMed ID: 29180619
[TBL] [Abstract][Full Text] [Related]
56. Systematic identification and analysis of mammalian small ubiquitin-like modifier substrates.
Gocke CB; Yu H; Kang J
J Biol Chem; 2005 Feb; 280(6):5004-12. PubMed ID: 15561718
[TBL] [Abstract][Full Text] [Related]
57. PIAS1 negatively regulates ubiquitination of Msx1 homeoprotein independent of its SUMO ligase activity.
Song YJ; Lee H
Mol Cells; 2011 Sep; 32(3):221-6. PubMed ID: 21717107
[TBL] [Abstract][Full Text] [Related]
58. Protein inhibitor of activated signal transducer and activator of transcription 1 interacts with the N-terminal domain of mineralocorticoid receptor and represses its transcriptional activity: implication of small ubiquitin-related modifier 1 modification.
Tallec LP; Kirsh O; Lecomte MC; Viengchareun S; Zennaro MC; Dejean A; Lombès M
Mol Endocrinol; 2003 Dec; 17(12):2529-42. PubMed ID: 14500761
[TBL] [Abstract][Full Text] [Related]
59. Casein kinase-2-mediated phosphorylation increases the SUMO-dependent activity of the cytomegalovirus transactivator IE2.
Tripathi V; Chatterjee KS; Das R
J Biol Chem; 2019 Oct; 294(40):14546-14561. PubMed ID: 31371453
[TBL] [Abstract][Full Text] [Related]
60. Su(var)2-10 and the SUMO Pathway Link piRNA-Guided Target Recognition to Chromatin Silencing.
Ninova M; Chen YA; Godneeva B; Rogers AK; Luo Y; Fejes Tóth K; Aravin AA
Mol Cell; 2020 Feb; 77(3):556-570.e6. PubMed ID: 31901446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
